Compare Amphastar Pharmaceuticals Inc (AMPH) vs Under Armour Inc Class A (UA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Under Armour (UA) trades at $6.61, up 2.48% with a bullish technical signal from moving averages. The company reported mixed Q1 2026 results with an EPS miss but maintains a 40.3% analyst buy rating. Recent financials show revenue of $5.16B for 2025 with negative net income of -$201.27M, though gross margins remain healthy at 45.48%. The Dodge collaboration and institutional buying by Prem Watsa provide positive catalysts amid ongoing business restructuring.

The outlook remains challenging with declining revenue projections and negative profitability metrics, but current valuation at 0.57 P/S offers potential for turnaround investors. Key risks include sustained revenue declines, competitive pressures, and negative cash flow trends. Institutional sentiment appears cautiously optimistic despite fundamental headwinds.